50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
One Stock Doubles Your Money, During Crisis? (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
One Stock Doubles Your Money, During Crisis? (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
NYSE:BHVN

Biohaven Pharmaceutical - BHVN News Today

$151.97
+0.21 (+0.14%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$151.52
$152.16
50-Day Range
$145.95
$151.97
52-Week Range
$79.01
$152.16
Volume
2.19 million shs
Average Volume
1.04 million shs
Market Capitalization
$10.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.17
Get Biohaven Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.



BHVN Media Mentions By Week

BHVN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BHVN
News Sentiment

1.00

0.52

Average
Medical
News Sentiment

BHVN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BHVN Articles
This Week

2

3

BHVN Articles
Average Week

SourceHeadline
MarketBeat logoBiohaven Pharmaceutical (NYSE:BHVN) Sets New 1-Year High at $152.10
americanbankingnews.com - September 25 at 4:14 AM
finance.yahoo.com logoReal-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
finance.yahoo.com - August 31 at 10:38 AM
msn.com logoBiohaven Pharmaceutical's Return On Capital Employed Overview
msn.com - August 26 at 4:49 PM
seekingalpha.com logoBiohaven: Non-Standard Merger Consideration Makes This A Buy
seekingalpha.com - August 17 at 12:18 PM
msn.com logoWhy These Pfizer Analysts Like The Global Blood Therapeutics Deal
msn.com - August 10 at 11:58 AM
finance.yahoo.com logoGet ready for more merger mania in the pharma sector for the rest of the year
finance.yahoo.com - August 9 at 4:53 PM
finance.yahoo.com logoBiohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat
finance.yahoo.com - August 8 at 3:48 PM
finance.yahoo.com logoBiohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
finance.yahoo.com - August 5 at 8:14 AM
finance.yahoo.com logoClearBridge Investments Trimmed its Position in Biohaven Pharmaceutical (BHVN)
finance.yahoo.com - August 3 at 9:11 PM
apnews.com logoSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates COWN, SWIR, BHVN, GLTA
apnews.com - August 3 at 11:10 AM
nasdaq.com logoNotable ETF Outflow Detected - IWM, BHVN, SWAV, HALO
nasdaq.com - July 28 at 7:54 PM
finance.yahoo.com logoAmerican Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
finance.yahoo.com - July 28 at 8:52 AM
apnews.com logoThe M&A Class Action Firm Continues Investigating the Merger
apnews.com - July 26 at 2:31 PM
nasdaq.com logoNoteworthy Tuesday Option Activity: BHVN, F, SI
nasdaq.com - July 19 at 8:28 PM
nasdaq.com logoIWM, BHVN, SWAV, HALO: Large Outflows Detected at ETF
nasdaq.com - July 16 at 9:24 PM
apnews.com logoINVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, GRRB, SIMO, MN
apnews.com - July 13 at 2:14 PM
finance.yahoo.com logoBiohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
finance.yahoo.com - July 7 at 7:43 AM
morningstar.com logoBiohaven Pharmaceutical Holding Co Ltd - Stock News
morningstar.com - July 7 at 2:33 AM
apnews.com logoINVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, PCSB, NLSN
apnews.com - July 7 at 2:33 AM
nasdaq.com logoPfizer Stock: Plenty Left in the Vial Despite COVID-19 Waning
nasdaq.com - June 29 at 6:16 AM
apnews.com logoINVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, USWS, HR, SREV
apnews.com - June 28 at 3:15 PM
finance.yahoo.com logoAbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
finance.yahoo.com - June 22 at 4:41 PM
finance.yahoo.com logoBiohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 4:55 PM
finance.yahoo.com logoBiohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
finance.yahoo.com - June 9 at 11:55 AM
apnews.com logoSHAREHOLDER UPDATE: Halper Sadeh LLP Investigates HMTV, BHVN, MANT, SWCH
apnews.com - June 6 at 12:50 PM
markets.businessinsider.com logoSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, SWCH
markets.businessinsider.com - June 1 at 6:56 AM
finance.yahoo.com logoBiohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Is Breakeven Near?
finance.yahoo.com - May 24 at 4:38 PM
finance.yahoo.com logoBiohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
finance.yahoo.com - May 24 at 11:36 AM
finance.yahoo.com logoBiogen Needs a New CEO. Here Are Some Options.
finance.yahoo.com - May 24 at 11:36 AM
reuters.com logoBiohaven's drug for genetic neurological disease fails late-stage study
reuters.com - May 23 at 10:23 PM
apnews.com logoSHAREHOLDER ALERT: Halper Sadeh LLP Investigates BHVN, SWCH, TREC, MICT
apnews.com - May 23 at 5:23 PM
seekingalpha.com logoBiohaven gets FDA review for nasal spray zavegepant to treat migraine
seekingalpha.com - May 23 at 5:23 PM
seekingalpha.com logoBiohaven phase 3 trial in genetic muscle disorder fails to reach significance overall due to low disease progression
seekingalpha.com - May 23 at 5:23 PM
finance.yahoo.com logoUS FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
finance.yahoo.com - May 23 at 5:23 PM
finance.yahoo.com logoUPDATE 2-Biohaven's drug for neurological disease fails late-stage study
finance.yahoo.com - May 23 at 5:23 PM
finance.yahoo.com logoBiohaven's Neurological Disease Candidate Flunks In Late-Stage Study
finance.yahoo.com - May 23 at 5:23 PM
seekingalpha.com logoGlobal Blood, Impel Pharma could be M&A targets after Biohaven deal - analysts
seekingalpha.com - May 15 at 6:07 PM
benzinga.com logoShareholder Alert - The M&A Class Action Firm Announces an Investigation of BioHaven Pharmaceutical Holding Company Ltd. - BHVN
benzinga.com - May 13 at 10:59 PM
finance.yahoo.com logoPfizer Turns to Unusual Deal Structure to Buy Biohaven Drugs
finance.yahoo.com - May 13 at 4:12 AM
nasdaq.com logoJanuary 2023 Options Now Available For Biohaven Pharmaceutical Holding (BHVN)
nasdaq.com - May 11 at 3:06 PM
finance.yahoo.com logoPfizer is Acquiring a Migraine Fixer for $11.6 Billion
finance.yahoo.com - May 11 at 12:23 AM
benzinga.com logoBIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm
benzinga.com - May 10 at 7:23 PM
finance.yahoo.com logoNasdaq Leads Upside As Indexes Pull Back Into The Close; This Dow Jones Stock Nears Buy Point
finance.yahoo.com - May 10 at 7:23 PM
investorplace.com logoWhy Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
investorplace.com - May 10 at 6:03 PM
proactiveinvestors.com.au logoPfizer splashes $11.6bn of vaccine cash on Biohaven Pharmaceutical Holding
proactiveinvestors.com.au - May 10 at 2:22 PM
apnews.com logoBHVN Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Biohaven Pharmaceutical to Pfizer
apnews.com - May 10 at 2:22 PM
markets.businessinsider.com logoPfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal
markets.businessinsider.com - May 10 at 2:22 PM
finance.yahoo.com logoPfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
finance.yahoo.com - May 10 at 2:22 PM
finance.yahoo.com logoStock Market Fades, Mixed At Midday; A Defensive Group Sells Off
finance.yahoo.com - May 10 at 2:22 PM
markets.businessinsider.com logoBiohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments
markets.businessinsider.com - May 10 at 8:17 AM
Get Biohaven Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

This page (NYSE:BHVN) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.